Background: ALPPS is a two-stage hepatectomy that induces more rapid liver growth compared to conventional strategies. This report aims to establish a risk-score to avoid adverse outcomes of ALPPS only for patients with colorectal liver metastases (CRLM) as primary indication for ALPPS. Methods: All patients with CRLM included in the ALPPS registry were included. Risk score analysis was performed for 90-day mortality after ALPPS, defined as death within 90 days after either stage. Two risk scores were generated i.e. one for application before stage-1, and one for application before stage-2. Logistic regression analysis was performed to establish the risk-score. Results: In total, 486 patients were included, of which 35 (7%) died 90 days after stage-1 or 2. In the stage-1 risk score, age ≥67 years (OR 3.7), FLR/BW ratio <0.40 (OR 2.9) and total center-volume (OR 2.4) were included. For the stage-2 score age ≥67 years (OR 3.7), FLR/BW ratio <0.40 (OR 2.8), bilirubin 5 days after stage-1 >50 μmol/L (OR 2.4), and stage-1 morbidity grade IIIA or higher (OR 6.3) were included. Conclusions: The CRLM risk-score to predict mortality after ALPPS demonstrates that older patients with small remnant livers in inexperienced centers, especially after experiencing morbidity after stage-1 have adverse outcomes. The risk score may be used to restrict ALPPS to low-risk patient populations.

Additional Metadata
Persistent URL dx.doi.org/10.1016/j.hpb.2018.11.010, hdl.handle.net/1765/113806
Journal HPB
Rights no subscription
Citation
Huiskens, J, Schadde, E. (Erik), Lang, H. (Hauke), Malago, M. (Massimo), Petrowsky, H. (Henrik), de Santibañes, E. (Eduardo), … Olthof, P.B. (Pim B.). (2019). Avoiding postoperative mortality after ALPPS–development of a tumor-specific risk score for colorectal liver metastases. HPB. doi:10.1016/j.hpb.2018.11.010